This additional risk minimisation material is for Apixaban 2.5 mg and 5 mg film coated tablet from Marketing Authorisation Holder, Silicon Pharma Limited. Please ensure that you are familiar with this material before prescribing Apixaban Tablets as it contains important safety information on the potential risk of bleeding during treatment and provides guidance on how to manage that risk. Prescriber Guide is approved by MHRA in 11/2025. This is for UK Only additional risk minimisation material.